ReviewMayo Clinic proceedings. Digital health2025
Much More Than the Malady: The Promise of a Web-Based Digital Platform Incorporating Self-Report for Research and Clinical Care in Mild Cognitive Impairment.
Review in Mayo Clinic proceedings. Digital health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Facial phenotypes in Alzheimer's disease: from neurobiology to artificial intelligence.Alzheimer's research & therapy · 2026Review
- Speech-based digital endpoints track ALS progression and align with standard clinical outcomes: evidence from the VRG50635 trial.Scientific reports · 2026Article
- Digital Health Technologies Applied in Patients With Early Cognitive Change: Scoping Review.Journal of medical Internet research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Traditional clinical trials in neurodegenerative disorders have utilized combinations of examination-based outcomes, global assessments by investigators and participants, and scales aimed at function, some of which are patient-reported outcomes. It is debatable whether these tools optimally convey therapeutic efficacy. A complementary approach using digital biomarkers to surpass exam-based limitations for detecting physical change coupled with a direct report from participants on what their sources of suffering are could be a useful advance in reporting beneficial effects of interventions, particularly if changes track together. We sought to determine the feasibility of remotely assessing speech, facial features, and cognition in an mild cognitive impairment (MCI) population, whether those extracted features could distinguish MCI from controls, and to explore what self-reported problems could reveal about the MCI experience. Our web-based platform was easy to use and revealed facial features in particular as capable of discriminating MCI from controls. Using the features that showed a statistically significant difference between cohorts (
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.